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The review article published in this
issue, concerning new options for pre-
ventive drug treatment of migraine,
deals with a subject that always draws
the attention of both general practi-
tioners and neurologists because of the
high frequency with which they are
confronted with doubts related to treat-
ment in everyday practice. Several
drugs are reported to be useful and
consequently are used for both acute
and preventive treatment of migraine
attacks, with a wide range of efficacy
between them that probably arises from
different individual responses, which
arise from different pathophysiologic
factors that may be involved in each
case. Several drugs have been tested
for their therapeutic efficacy in well-
conducted, double-blind, placebo-con-
trolled clinical trials. Nevertheless, pa-
tients often have a disappointing clini-
cal response. From time to time, re-
view articles are published on the sub-
ject1,2, and although they suggest that
several drugs are efficient in decreas-
ing migraine frequency and/or inten-
sity, they also show that we are far from
identifying the ideal drug. This failure
is most certainly related to our poor
understanding of the basic disease
mechanisms. Perhaps it would be more
appropriate to address migraine as a
group of closely related entities, since
there are different types of migraine
(with differences in the intensity, trig-
gering, and associated factors, pres-
ence or absence of the different types
of aura, etc.), probably with different
pathophysiologic etiologies.
Even the mechanisms of action of
the various drugs that are used in pre-
ventive migraine treatment are not
fully understood.
The placebo effect is particularly
high, not only in preventive therapy,
but also in the acute phase, ranging
from 20% to 70%, according to reports
in the literature4. This fact only adds
to the difficulties in studying drug ef-
ficacy in a disease in which psycho-
somatic or other environmental factors
seem to play such an important role in
its symptomatic expression. Therefore,
even studies that adhere to the strict
rules of scientific research must be in-
terpreted with caution when they test
a new drug option. Other investigators
must retest these drugs before they can
be accepted as really useful. The re-
view article reports on the efficacy of
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several drugs that have been tested
and still have not been widely used in
preventive migraine therapy.
Reports on the efficacy of ribofla-
vin and magnesium salts were origi-
nally published some years ago. These
are low cost-therapies and ideally
should be studied further to make sure
that their efficacy is reliable, and their
adverse-effect rate is low enough to al-
low them to be incorporated into our
prescriptions.
The efficacy of antiepileptic drugs
in preventive migraine therapy is a
long story that waxes and wanes over
the time. Several of the traditional
drugs, such as phenobarbital, pheny-
toin, carbamazepine, and more re-
cently, divalproate, were or are still
used, with efficacy reported eventually
for all of them over the years, but sel-
dom proven, except regarding
divalproate. The new antiepileptic
drugs—gabapentin, topiramate,
zonisamide, tiagabine, and
levetiracetam, which were reviewed in
the article in this issue—have only
scant data on their efficacy (most of the
references cited were published as ab-
stracts). Lamotrigine, another recently
marketed antiepileptic drug, has also
been tested, and it proved ineffective
with migraines3. On the other hand, all
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these newer drugs are much more ex-
pensive than the traditional drugs used
nowadays, a problem that is particu-
larly important in developing coun-
tries. The high-cost problem also will
limit the use of botulinum toxin.
Concerning the other drugs,
montelukast and lisinopril, their effi-
cacy and place in migraine treatment
is welcome if proven over the years,
because positive results following
treatment with these drugs will also
add to our understanding of the basic
pathophysiologic mechanisms of the
disease.
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